Clinical trials: Mask
Non-infectious Anterior Uveitis
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
- Trial name
- NCT07136805
- Testing
- VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetate
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- VivaVision Biotech, Inc
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Dry Eye
A Clinical Trial to Assess Subjects With Dry Eye Disease.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT04971031
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Anesthesia
AuraOnce Performance Observation
This study is designed as a single-center, prospective observational, non-controlled, non-interventional study with an investigation period lasting for one day (during one bronchoscopy procedure).
- Trial name
- NCT04128527
- Testing
- Placement of laryngeal mask
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Ambu A/S
Acute Viral Conjunctivitis
FST-100 in the Treatment of Acute Viral Conjunctivitis
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis.
- Trial name
- NCT01461954
- Testing
- FST-100, FST-100 Vehicle
- Where
- 2 sites in United States, Brazil
- Volunteers
- 132 people
- Sponsor
- Shire
Retinal Disease
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Trial name
- COMFORT (NCT05750589)
- Testing
- IRX-101, Providone-Iodine
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Glaucoma, Ocular Hypertension
AR-12286 in Combination With Latanoprost
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
- Trial name
- NCT01302249
- Testing
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Skin Aging
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
This research study will test how well a light therapy mask works for women with mild to moderate hyperpigmentation (brown spots) and moderate to severe facial wrinkles, as compared to a "sham" or inactive investigational light…
- Trial name
- NCT03312543
- Testing
- Active Mask
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Healthy Volunteers
The Effect of Home and Hospital Mask Designs on Respiratory Variables in Healthy Volunteers
The goal of this randomized cross-over study is to investigate whether the design of non-invasive ventilation (NIV) mask impacts respiratory variables in healthy volunteers on NIV therapy.
- Trial name
- NCT07463716
- Testing
- Non-invasive ventilation (NIV)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fisher and Paykel Healthcare
Painful Diabetic Peripheral Neuropathy (PDPN)
Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy…
- Trial name
- ENFORCE (NCT06715462)
- Testing
- N0750, Cymbalta®, Lyrica®
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Thyroid Eye Disease, TED, Graves Orbitopathy
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
- Trial name
- ORBIT (NCT07753603)
- Testing
- linsitinib
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sling Therapeutics, Inc.
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Cataract
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300.
- Trial name
- NCT06383273
- Testing
- MELT-300 sublingual tablet, Midalozam sublingual tablet
- Where
- 12 sites in United States
- Volunteers
- 528 people
- Sponsor
- Melt Pharmaceuticals
Dry Eye Syndromes
3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
This study is a prospective, multicentre, parallel-group, active-controlled, non-inferiority study conducted in adult patients with moderate-to-severe dry eye disease (DED) related to keratitis or keratoconjunctivitis.
- Trial name
- ALHENA (NCT04685109)
- Testing
- Alocross 0.2% Unit Dose, Vismed
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- Santen SAS
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Presbyopia
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia.
- Trial name
- OPSIS (NCT05665387)
- Testing
- 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution
- Where
- 12 sites in United States
- Volunteers
- 79 people
- Sponsor
- Santen Inc.
Wet Age Related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- MOJAVE (NCT07816315)
- Testing
- OLN324, Aflibercept
- Volunteers
- 500 people
- Sponsor
- Ollin Biosciences, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered…
- Trial name
- NCT04657289
- Testing
- Ranibizumab, Port Delivery System with Ranibizumab
- Where
- 104 sites in Argentina, Australia and 14 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.